Join
Live feed
·
PRReleasevia Quantisnow
CervoMed Inc. logo

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

ByQuantisnow·Wall Street's wire, on your screen.
CRVO· CervoMed Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRVO (CervoMed Inc.) and more on Quantisnow.